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tive immune responses, which have the potential both to poten-
tiate and reduce the activity ofOVs.Natural killer (NK) cells can
mediate potent anti-viral and anti-tumoral responses, but there
are no data on the role of NK cells in oncolytic adenovirus
activity. Here, we have used two different oncolytic adenovi-
ruses—the Ad5 E1A CR2-deletion mutant dl922-947 (group
C) and the chimeric Ad3/Ad11pmutant enadenotucirev (group
B)—to investigate the effect of NK cells on overall anti-cancer
efficacy in ovarian cancer. Because human adenoviruses do
not replicate in murine cells, we utilized primary human NK
cells from peripheral blood and ovarian cancer ascites. Our
results show that dl922-947 and enadenotucirev do not infect
NK cells, but induce contact-dependent activation and anti-can-
cer cytotoxicity against adenovirus-infected ovarian cancer
cells. Moreover, manipulation of NK receptors DNAM-1
(DNAXaccessorymolecule-1) andTIGIT (T cell immunorecep-
torwith Ig and ITIMdomains) significantly influencesNKcyto-
toxicity against adenovirus-infected cells. Together, these
results indicate that NK cells act to increase the activity of onco-
lytic adenovirus in ovarian cancer and suggest that strategies to
augment NK activity further via the blockade of inhibitory NK
receptor TIGIT could enhance therapeutic potential of OVs.Received 10 September 2019; accepted 10 February 2020;
https://doi.org/10.1016/j.omto.2020.02.001.
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Oncolytic viruses (OVs) infect malignant cells and replicate selec-
tively within them. This selective replication induces direct cytotox-
icity and also triggers profound innate and adaptive immune
responses,1–3 which have the potential both to potentiate and reduce
the anti-cancer activity of the OVs.4
Oncolytic adenoviruses have shown potential as cancer therapeutics
in multiple pre-clinical tumor models,5–7 and the first oncolytic virus
licensed for routine clinical practice was an adenovirus.8 Two onco-
lytic adenoviruses were evaluated in this work: the E1A CR2-deleted
Ad5 mutant dl922-947, which we have previously shown has signifi-
cant efficacy in ovarian cancer models,9,10 and the chimeric Ad3/
Ad11p mutant enadenotucirev, which was generated by directed
evolution11 and is currently being tested in early phase clinical trialsMolecular
This is an open access article under tin ovarian (ClinicalTrials.gov: NCT02053220)12 and other cancers
(ClinicalTrials.gov: NCT02028117).
Natural killer (NK) cells are a group of effector innate immune cells
that can mediate potent anti-viral and anti-tumoral responses (re-
viewed in Jos and Altfeld13 and Marcus et al.14). In the context of on-
colytic virotherapy, NK cells activated by the viral infection could
potentially lead to efficient elimination of the infected cancer cells,
but rapid clearance of virus-infected cells may also prevent the spread
of OVs and reduce overall activity. Previous studies suggested that
NK cells are activated by oncolytic reovirus treatment in patients15
and are necessary for successful maraba virus therapy in murine
models.16 By contrast, NK cells may limit the efficacy of an oncolytic
herpes simplex virus 1 (HSV-1) in murine glioblastoma models,17
which may be reversed by transforming growth factor-b (TGF-b)18
and the proteasome inhibitor bortezomib.19 Although the role of
NK cells in oncolytic adenovirus therapy has not been thoroughly
explored, expression of Ad5 E1A protein can sensitize tumor cells
to NK-mediated lysis,20 and several studies have implicated NK cells
in the elimination of non-replicating E1-deleted adenovirus
vectors.21,22
Here, we evaluated the role of NK cells in the efficacy of oncolytic
adenoviral therapy in ovarian cancer. Species-specific replication of
adenoviruses and the subsequent lack of in vivo immunocompetent
model systems23 have hindered the understanding of immune re-
sponses to oncolytic adenoviral infections. To circumvent these short-
comings, we used primary NK cells isolated both from peripheral
blood and ovarian cancer ascites to investigate the influence of NK
cells in oncolytic adenoviral therapy in ovarian cancer. We show
that NK cells augment the activity of oncolytic adenoviruses in a
manner that is contact dependent and involves NK activatingTherapy: Oncolytics Vol. 16 March 2020 ª 2020 The Author(s). 289
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Molecular Therapy: Oncolyticsreceptor DNAM-1 (DNAX accessory molecule-1). Furthermore,
blockade of NK inhibitory receptor TIGIT also augments the effec-
tiveness of oncolytic adenoviruses.
RESULTS
Adenovirus Is Unable to Infect NK-92 and Primary
Hematopoietic Cells from Ovarian Cancer Ascites
The ability of human adenoviruses to infect human immune cells,
including NK cells, was assessed using Ad-GFP, a non-replicating
adenovirus type 5 encoding green fluorescent protein (GFP) under
the control of the CMV (cytomegalovirus) immediate early promoter,
dl922-947 and NG-107, a GFP-encoding derivative of enadenotu-
cirev. There was no detectable fluorescence in the established NK
cell line NK-92 following Ad CMV GFP infection (Figure S1A), in
contrast to a panel of ovarian cancer (OC) cells (p = 0.0002). Adeno-
viral protein expression was detected by immunofluorescence in
TOV21G, but not peripheral blood NK (pNK) cells, after infection
with dl922-947 (Figure S1B). Similarly, there was no detectable
GFP fluorescence in CD45+ populations isolated from peripheral
blood mononuclear cells (PBMCs) and ascites after incubation with
Ad CMV GFP (Figure S1C), nor in pNK after incubation with NG-
107 (Figure S1D). Thus, effects seen in subsequent experiments did
not result from direct infection of immune cells by adenovirus.
Upregulation of CD69, CD107a, and Interferon-g (IFN-g)
Because NK-92 cells have high basal expression of degranulation
marker CD107a (Figure S2), the influence of oncolytic adenoviral
infection onNK cell activation status was assessed in pNK cells. Co-cul-
ture of pNK with dl922-947-infected TOV21G and OVCAR4 cells led
to upregulation of both CD69 and CD107a on pNK compared to
mock-infected controls (Figure 1A). The CD69 average MFI (mean
fluorescence intensity) increased significantly for both TOV21G
(mean fold change 2.1, 95% confidence interval (CI) 1.4–2.7 p =
0.0022) and OVCAR4 (mean fold change 1.4, 95% CI 1.1–1.6, p =
0.0023). CD107a positivity also increased significantly from 4.2% to
11.2% for TOV21G (mean difference 7.0%, 95% CI 4.1%–9.9%, p =
0.001); a similar, albeit non-significant, trend was observed for OV-
CAR4 (Figure 1B). There were also significant increases in IFN-g levels
in cell-free supernatants following pNK co-culture (Figure 1C)—IFN-g
concentration increased 7-fold (median 22 pg/mL to 157 pg/mL, p =
0.03, n = 6 independent experiments) for TOV21G and nearly 4-fold
(median 29 pg/mL to 114 pg/mL, p = 0.003) for OVCAR4 (Figure 1C).
Similarly, co-culture of pNK with enadenotucirev-infected TOV21G
also led to a significant increase in CD69 expression (mean fold
change 1.8, 95% CI 1.2–2.4, p = 0.0162) and IFN-g release (median
increase 3,679 pg/mL, p = 0.03) on pNK, as well as a trend toward
CD107a upregulation (Figures 1B and 1C). Co-culture with enadeno-
tucirev-infected OVCAR4 also led to increases in CD69 (Figure 1B,
p = 0.034) and IFN-g (Figure 1C, p < 0.0001) on pNK, although
not CD107a. The observed NK activation for both viruses was depen-
dent on contact with virus-infected OC cells, as exposure to condi-
tioned medium alone did not upregulate CD69 or CD107a, nor did
it increase IFN-g production in any pNK group assessed (Figure S3).290 Molecular Therapy: Oncolytics Vol. 16 March 2020Oncolytic Adenovirus Augments Peripheral Blood and Ascites
NK-Mediated Anti-tumoral Cytotoxicity
We next used live cell imaging to quantify virus-induced NK cytotox-
icity. In keeping with their high levels of basal activation (Figure S2),
NK-92 alone led to significant killing of mock-infected TOV21G (Fig-
ure 2A) and OVCAR4 (Figure 2B) cells. However, NK-92 co-culture
was able to augment both dl922-947 (increase in mean total area un-
der curve [TAUC] of fluorescence over time 35,059 units, 95% CI
15,801–54,317, p = 0.001; Figure 2A) and enadenotucirev cytotoxicity
(Figure 2C) in TOV21G cells compared to respective virus infection
and NK alone. In OVCAR4 experiments, similar results were
following both dl922-947 (increase in TAUC 30,632 units, 95% CI
21,405–39,860, p < 0.0001; Figure 2B) and enadenotucirev (Figure 2D)
infection compared to virus and NK alone.
Unlike NK-92 cells, pNK alone did not kill mock-infected ovarian
cancer cells (Figures 3A and 3B). However, pNKwere able to augment
dl922-947 (Figure 3A) and enadenotucirev (Figure S4) cytotoxicity
against TOV21G, when compared either to virus infection or pNK
treatment alone. In OVCAR4 experiments, pNK also augmented
dl922-947 (p = 0.016; Figure 3B), but not enadenotucirev (Figure S4),
cytotoxicity compared with virus infection and NK alone.
To validate the live cell imaging results, we usedflowcytometry to assess
the viability of dl922-947-infected TOV21G cells. Significantly greater
tumor cell death was observed when pNK were co-cultured with
dl922-947-infectedTOV21G, compared tovirus infection orpNK treat-
ment alone (Figure 3C; n = 5, mean difference = 18.3% and 35.7%, 95%
CI 2.1%–34.6% and 7.2%–64.3%, p = 0.0342 and 0.024, respectively).
NK cells were also purified from ascites from two patients with
advanced ovarian high-grade serous carcinoma (Figure S5) and co-
cultured with TOV21G, with or without dl922-947 infection. As
with pNK, purified ascites NK cells increased cytotoxicity of dl922-
947-infected TOV21G, compared to dl922-947 infection and NK
alone in two separate experiments (Figure 3D). Interestingly, ascites
NK cells from patient 2 had a modest cytotoxic effect on uninfected
TOV21G cells (Figure 3D).
Oncolytic Adenoviruses Promote NK-Mediated Cytotoxicity of
Uninfected Tumor Cells
To evaluate whether NK cells activated by oncolytic adenoviruses
could promote killing of uninfected tumor cells, we co-cultured unin-
fected tumor cells marked by cell tracker with pNK cells conditioned
by exposure to either dl922-947- or enadenotucirev-infected tumor
cells. Conditioned pNK cells induced additional cytotoxicity against
both TOV21G (n = 5, p = 0.026 and 0.037, respectively) andOVCAR4
(n = 5, p = 0.030 and 0.028, respectively), when compared to pNK
conditioned by mock-infected tumor cells (Figures 4A and 4B).
Contact-Dependent Interactions between Oncolytic Adenovirus
and NK
Soluble factors released from adenovirus-infected malignant cells
alone were unable to augment NK cytotoxicity against uninfected
Figure 1. NK Cells Are Activated by Adenovirus-Infected OC Cells
(A) Representative images of CD69 (left) and CD107a (right) expression on NK cells. (B) Summary analyses of independent experiments (n = 5) for CD69 (left) and CD107a
(right) expression on NK cells (Wilcoxon signed rank tests). (C) Summary analyses of IFN-g expression in pNK co-culture with OV-infected TOV21G (n = 6) and OVCAR4 (n =
2). Individual data points plotted for OVCAR4 (Wilcoxon signed rank test). M, mock; 922, dl922-947; En, enadenotucirev; K, positive control (co-culture with K562).
www.moleculartherapy.orgtarget cells (Figures 4C and 4D), suggesting that direct contact be-
tween NK and virus-infected malignant cells was essential. To assess
further whether cell-cell contact was a pre-requisite for the
augmented NK anti-tumoral cytotoxicity, we compared cell death
in dl922-947-infected cells in transwell inserts under different condi-
tions (Figure 4E). Consistent with Figure 3, in the transwells in which
NK cells and virus-infected TOV21G cells were in direct contact,
there was significantly more cell death compared to virus infection
alone (Figure 4E, group 1 versus 2; mean difference = 15.3%, 95%
CI 6.8%–23.7%, p = 0.007). However, where there was no direct con-tact (Figure 4E, group 3 versus 4), there was no difference in the pro-
portion of dead TOV21G cells within the transwell inserts, indicating
a lack of contact-independent killing.
Expression of Selected NK Ligands and Receptors after
Oncolytic Adenovirus Infection
MHC class I was downregulated on the surface of OC cells after infec-
tion with dl922-947 but not Ad3/11 enadenotucirev (Figure 5A; Fig-
ure S6A; p = 0.039) or non-replicating Ad5 adenovirus Ad LM-X
(data not shown).We found no change in CD112, CD155 (Figure 5A),Molecular Therapy: Oncolytics Vol. 16 March 2020 291
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www.moleculartherapy.orgMICA/B, or CD58 (data not shown) expression following dl922-947
infection. In addition, using recombinant human Fc chimeras (Fig-
ure 5B), we did not detect any change in expression of ligands that
bind to NKG2D, NKp30, NKp44, and NKp46 on TOV21G and OV-
CAR4 after infection with either dl922-947 or enadenotucirev (Fig-
ure 5C; Figure S6B).
Despite the absence of changes in CD112 and CD155 expression, we
observed a significant increase in binding of DNAM-1 recombinant
human Fc chimera on TOV21G following dl922-947 infection (Fig-
ure 5D; p = 0.024), but not enadenotucirev infection. A similar trend
was observed in OVCAR4, although this did not reach statistical sig-
nificance. To explore this further, we analyzed the expression of the
paired receptors DNAM-1 and TIGIT, as well as CD96 and NKp46,
on pNK cells following co-culture with TOV21G cells (both unin-
fected or adenovirus-infected) or conditioned medium (Figures 6A
and 6B; Figure S7). There was no significant difference between the
expression of NK receptors CD96 and NKp46 (Figure S7). However,
co-culture of pNK with OC significantly reduced the expression of
DNAM-1 (p = 0.04, Figures 6A and 6B) and enhanced the expression
of TIGIT (p < 0.0001, Figures 6A and 6B) compared to conditioned-
medium, independent of virus infection.
The Role of DNAM-1 and TIGIT in NK Cytotoxicity against dl922-
947-Infected Cells
Finally, we evaluated the effect of DNAM-1 and TIGIT blockade on
NK cell activity against dl922-947-infected cells (Figures 6C and
6D). As previously, the addition of pNK augmented cytotoxicity of
dl922-947 in both TOV21G and OVCAR4 cells. DNAM-1 blockade
alone, in the absence of NK cells, had no effect on dl922-947 efficacy
in either cell line. DNAM-1 blockade also had no significant effect on
the efficacy of NK cells against uninfected cancer cells. In contrast,
DNAM-1 blockade consistently reduced cytotoxicity in both dl922-
947-infected TOV21G (decrease in TAUC 11,319 units; p = 0.008)
and OVCAR4 (decrease in TAUC 1,271 units; p = 0.03) when co-
cultured with NK cells. We also evaluated the effect of TIGIT
blockade on NK cytotoxicity against OV-infected cells (Figure 6E),
with mock-infected and NK-only groups as controls (Figure S8).
Compared to NK alone, the addition of TIGIT blockade significantly
augmented NK cytotoxicity against dl922-947-infected TOV21G (in-
crease in TAUC 6,532 units, p = 0.003). A similar trend was observed
for enadenotucirev-infected TOV21G (increase in TAUC 5,069
units), although the difference did not reach statistical significance.
DISCUSSION
Oncolytic viruses have the ability to induce potent immune responses,
and recent data suggest that this could prime tumor cells for immune
checkpoint blockade.2,3 However, NK cells have the ability to elimi-Figure 2. NK-92 Cells Increase Cytotoxicity of Oncolytic Adenovirus
NK-92 cytotoxicity against TOV21G and OVCAR4 infected with dl922-947 (MOI 10, 4
Fluorescent counts over time from individual experiments (left) and summary data (right)
TOV21G + enadenotucirev (n = 5). (D) OVCAR4 + enadenotucirev (n = 6). Summary da
time (one-way ANOVA with multiple comparisons test).nate both virus-infected cells and malignant cells rapidly, which
may also prevent the spread of OVs and reduce OV activity. It was
previously shown that NK cells could impede anti-tumor activity of
an oncolytic HSV vector in vivo via NKp30 and NKp46.17 In this
study, we explored the role of NK cells in the activity of two different
oncolytic adenoviruses, dl922-947 and enadenotucirev, using primary
NK cells isolated from peripheral blood and ovarian cancer ascites—
the use of primary cells was necessary given the species specificity of
adenovirus replication.23
Overall, our results indicate that dl922-947 infection led to NK acti-
vation, as demonstrated by upregulation of CD69 and CD107a
expression, as well as IFN-g production. Enadenotucirev infection
also promoted IFN-g release and CD69 expression, with only modest
changes in CD107a. For both viruses, this activation was contact-
dependent, as exposure to cell-free conditioned medium from adeno-
virus-infected OC cells did not significantly increase CD69, CD107a,
or IFN-g.
Our results also indicate that all NK cells tested (NK-92, pNK, and as-
cites NK cells) augmented oncolytic adenovirus anti-tumor activities,
compared to either NK cells or oncolytic adenovirus alone. This in-
crease in cell death was observed both by conventional flow cytometry
at a single time point and by time-lapse microscopy over 24 h. The
changes were more pronounced for dl922-947 than enadenotucirev,
consistent with the greater changes in NK activation markers
observed. The effect was generally greater for pNK cells than was
observed in the two ascites NK cells tested. It is possible that ovarian
cancer ascites NK cells are less cytotoxic or have a more suppressed
phenotype than pNK—previous evidence suggested that expression
of activating receptors may be reduced on ascites NK cells in ovarian
cancer, leading to impaired cytotoxicity.24 However, further experi-
ments with a larger number of ascites samples would be required to
understand more fully the activation status of ascites NK cells and
their responsiveness to oncolytic virus infection. Like the NK cell acti-
vation, NK killing of oncolytic adenovirus-infected cells was contact-
dependent—soluble factors released from virus-infected cells alone
were insufficient to induce additional NK killing of uninfected target
cells.
Infection by a wide variety of viruses can influence NK activity via
inhibitory and activating NK receptors.13 Consistent with previous
reports,25 we found that MHC class I molecules were downregulated
after Ad5 oncolytic adenovirus infection, which could reduce anti-tu-
mor immune responses. In contrast, MHC class I molecules were un-
changed after Ad3/11 enadenotucirev and non-replicating Ad5
adenovirus infections. However, we saw no changes in MICA/B,
which contrasts with previous data that suggested that the adenovirus8 h) or enadenotucirev (MOI 100, 48 h) was assessed by time-lapse microscopy.
are presented: (A) TOV21G + dl922-947 (n = 5). (B) OVCAR4 + dl922-947 (n = 6). (C)
ta are expressed as total area under curve (TAUC) of fluorescent object counts over
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www.moleculartherapy.orgprotein E3 gp19K inducedMICA/B downregulation in foreskin fibro-
blasts.26 In addition to the deletion in E1A CR2,27 dl922-947 also con-
tains a 745 bp deletion in the E3B region that is replaced by 642 bp of
heterologous DNA.28,29 However, the region encoding gp19K within
E3A remains intact and the downregulation of MHC-I observed
following dl922-947 infection suggests that gp19K is functional.30,31
The mechanism underlying differences in MHC class I expression af-
ter dl922-947 (Ad5) and enadenotucirev (Ad3/11) infection could
also influence clinical anti-cancer efficacy and warrants further
investigation.
We investigated the paired NK receptors DNAM-1 and TIGIT as
DNAM-1 has previously been shown to play a key role in elimination
of both malignant32,33 and CMV-infected cells34 by NK cells. In
ovarian cancer specifically, the DNAM-1/CD155 interaction may be
crucial for NK-mediated lysis.35 We found that DNAM-1 expression
was decreased and TIGIT expression increased on NK cells following
co-culture with ovarian cancer cells, independent of virus infection.
However, the potential inhibitory effect of this change on NK was
partially overcome by dl922-947 infection as DNAM-1 ligands were
significantly upregulated after dl922-947 infection, as demonstrated
by increased binding to a DNAM-1 Fc-chimera. Critically, we also
found that DNAM-1 blockade significantly, albeit incompletely,
reduced pNK cytotoxicity against dl922-947-infected malignant cells,
but not against mock-infected cells.
Surprisingly, we were not able to demonstrate an increase in expression
of the twomain ligands forDNAM-1,CD155 (thePolioVirusReceptor/
Nectin-like protein 5) and CD112 (Nectin-2), by flow cytometry
following either dl922-947 or enadenotucirev infection. This suggests
either the presence of additional DNAM-1 ligands that are upregulated
following adenovirus infection or that adenovirus proteins may be able
to bind to DNAM-1 causing NK cell activation. A preliminary assess-
ment of the 36 adenovirus type 5 peptides identified three (III, IVa2,
and V) with at least partial alignment with the consensus amino acid
residues (DEGNYTC) critical forDNAM-1 interactions inNectin/Nec-
tin-like proteins, including CD112 and CD155,36 and thus potentially
able to activate DNAM-1 (Figure S9). The interactions between viral
and bacterial proteins and NK receptors have not been thoroughly
investigated, and a systematic exploration of individual adenovirus pro-
teins will be required to address these results fully. However, it has been
shown that Fap2 protein derived from Fusobacterium nucleatum pre-
sent in human colon can interact with TIGIT to inhibit NK cytotoxicity
against colon cancer.37
We also found that TIGIT blockade augmented pNK cytotoxicity,
reinforcing the importance of the DNAM-1/TIGIT axis in NK re-Figure 3. Peripheral Blood and Ascites NK Cells Increase the Cytotoxicity of O
Cytotoxicity of peripheral blood NK cells (pNK) or NK cells isolated from ovarian cancer as
enadenotucirev (MOI 100, 48 h) was assessed by time-lapse microscopy in (A), (B), a
Fluorescent counts over time from individual experiments (left) and summary data (right) a
represent the percentage of dead CD45 cells (TOV21G). (D) Cytotoxicity of aNK from p
test; error bars are not plotted when they are smaller than the symbol size).sponses against cancer cells infected with oncolytic adenoviruses. TI-
GIT is an inhibitory NK receptor that competes with DNAM-1 and
CD96 for ligand-binding.38,39 TIGIT is expressed on both T and
NK cells, where its expression is associated with T cell exhaustion
phenotypes.38 It is also upregulated in human malignancies and a
number of anti-TIGIT antibodies (e.g., etigilimab/OMP-313M32,
MTIG7192A, and AB154) are now being evaluated in early phase
clinical trials as anti-cancer agents.40
In summary, oncolytic adenovirus-infected ovarian cancer cells were
able to activate human NK cells and augment NK cytotoxicity
in vitro. For dl922-947, an Ad5 oncolytic adenovirus, this
augmented cytotoxicity was contact-dependent and involved modu-
lating the interactions between activating NK receptor DNAM-1
and virus-infected malignant cells. Although enadenotucirev, an on-
colytic group B adenovirus identified by its ability to propagate
selectively in carcinoma cells and kill them rapidly,41 also
augmented NK cytotoxicity, the effects were less marked than
with dl922-947 infection and did not appear to be associated with
DNAM-1. Further research will be required to evaluate additional
NK receptor-ligand pathways involved in the augmented NK cyto-
toxicity observed, particularly for enadenotucirev. Our results high-
light the lack of direct comparison of the efficacy of different onco-
lytic viruses and the importance of understanding the specific
immune responses against each oncolytic virus for maximizing ther-
apeutic benefits. Our demonstration that blockade of the paired NK
inhibitory receptor TIGIT further augmented NK cytotoxicity
against OV-infected cells suggests that the combination of oncolytic
adenovirus and TIGIT blockade may be a viable treatment strategy
in ovarian cancer.
MATERIALS AND METHODS
Cell Lines and Tissue Culture
Ovarian cancer cell lines OVCAR4 (NCI, Frederick, MA), TOV21G
(Fran Balkwill, Barts Cancer Institute, London, UK), erythroleukemia
cell line K562 (Vignir Helgason, University of Glasgow, Glasgow,
UK), and human NK cell line NK-92 (ATCC, Manassas, VA) were
incubated at 37C in 5% CO2. OVCAR4 and TOV21G were main-
tained in DMEM with 10% FBS, 2 mM L-Glutamine, and 100 mg/
mL penicillin/streptomycin. NK-92 cells were maintained in MEM-
alpha with 12.5% FBS, 12.5% horse serum, 2 mM L-Glutamine, and
5 ng/mL interleukin-2 (IL-2). K562 were maintained in RPMI with
10% FBS plus 2 mM L-Glutamine, and 100 mg/mL penicillin/strepto-
mycin. All lines were tested regularly for mycoplasma infection. All
human cancer cell lines were verified by short tandem repeat profiling
at the Cancer Research UK Beatson Institute using the Promega Gen-
ePrint 10 system (Promega, Southampton, UK). Human NK cellsncolytic Adenovirus
cites (aNK) against TOV21G and OVCAR4 infected with dl922-947 (MOI 10, 48 h) or
nd (D). Cytotoxicity of pNK against (A) TOV21G (n = 5) and (B) OVCAR4 (n = 4).
re presented. (C) Cytotoxicity of pNK against TOV21G (n = 5) by flow cytometry. Data
atient 1 and patient 2 against TOV21G (one-way ANOVA with multiple comparisons
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Figure 4. Activated NK Augmented Killing of
Uninfected Target Cells and Contact Dependence of
NK Cytotoxicity
Cytotoxicity of activated peripheral blood NK cells (pNK)
against cell-tracker marked and uninfected (A) TOV21G and
(B) OVCAR4was assessed by flow cytometry (n = 5 for each
line; paired t tests). Cytotoxicity of pNK against uninfected
(C) TOV21G (n = 5) and (D) OVCAR4 (n = 4) in the presence
or absence of conditioned medium (CM) from dl922-947-
infected TOV21G and OVCAR4, respectively. Cytotoxicity
was assessed using live-cell imaging. Fluorescence counts
over time from individual experiments (left) and summary
data (right) are presented. (E) Target TOV21G were infected
with dl922-947 (MOI 10, 48 h) in 12-well plates or in
transwell inserts (group 1–4). Cell-free medium control
(group 1) or pNK (group 2) were then incubated with virus-
infected TOV21G for 18 h. Cell death of TOV21G in trans-
wells (group 3 and 4), prevented from contact with NK cells
but exposed to the environment of group 1 and 2, was
compared by flow cytometry. The schematic representation
of each group is shown on the left, with summary results
(n = 5) on the right (paired t tests).
Molecular Therapy: Oncolyticswere isolated, resuspended in RPMI with 10% FBS plus 2 mM L-
Glutamine and 100 mg/mL penicillin/streptomycin, and used imme-
diately without additional IL-2 or IL-15.
Ethics Statement
Use of PBMCs isolated from samples from healthy blood donors
was approved by the Scottish National Blood Transfusion Service
(reference number 15-35). All donors gave written consent. Ascites
samples from patients with ovarian cancer undergoing drainage
for clinical purposes were collected under authority of the NHS
Greater Glasgow and Clyde Biorepository (UK Health Research296 Molecular Therapy: Oncolytics Vol. 16 March 2020Authority Research Ethics Committee reference
10/S0704/60). Use of ascites samples for this
project was then authorized by the NHS
Greater Glasgow and Clyde Biorepository Ac-
cess Committee (reference 16/WS/0207). All
patients gave written consent and samples
were anonymized.
Isolation of Peripheral Blood and Ascites-
Derived NK Cells
pNK cells were isolated from PBMCs using Easy-
Sep Human NK Cell Enrichment Kits (19055;
StemCell Technologies, Canada) according to
the manufacturer’s instructions. Human ovarian
cancer ascites samples were centrifuged at
2,500 rpm for 15 min at 18C (JS-4.2, Beckman-
Coulter, USA) in 250 mL centrifuge tubes.
The cell pellet was enriched using EasySep Hu-
man NK Cell Enrichment Kits before fluores-
cence-activated cell sorting (FACS) based onextracellular cell surface markers of NK cells (CD45+CD3CD56+).
The purity of primary NK cells (>90%) was confirmed by flow
cytometry.
Adenoviruses
The E1A CR2-deleted Ad5 vector dl922-947 and enadenotucirev,
an Ad3/Ad11p chimeric virus generated by directed evolution,
have both been previously described.11,29 Enadenotucirev was pro-
vided by PsiOxus Therapeutics (Oxford, UK). Ad CMV GFP is an
E1-deleted replication-deficient adenovirus type 5 vector express-
ing eGFP under the CMV immediate/early promoter. Reporter
Figure 5. NK Ligand Expression following Ad5
Adenovirus Infection
(A) TOV21G were infected with dl922-947 in triplicate
(MOI 10, 48 h). Expression of evaluation of MHC class I
(HLA-A, B, C; n = 4), CD112 (n = 4), and CD155 (n =
3) expression was assessed by flow cytometry (paired t
test). Evaluation of NK ligand expression on TOV21G
and OVCAR4 cells after dl922-947 infection (MOI 10,
48 h) using recombinant human Fc chimera proteins
DNAM-1, NKG2D, NKp30, NKp44, and NKp46. (B) A
schematic representation of the antigen-antibody com-
plex. The recombinant human Fc chimera protein can
bind to multiple ligands of the corresponding NK re-
ceptor. Summary data of independent experiments (n =
5 for each line) of (C) NKG2D, NKp30, NKp44, and
NKp46 ligand expression, and (D) DNAM-1 ligand
expression (paired t test).
www.moleculartherapy.orgenadenotucirev-based virus NG-107 (SSA promoter) also encodes
eGFP and was generated by Marino et al.42 Ad LM-X, a replica-
tion-defective adenovirus type 5 has been described previously.43
Viruses were expanded in 293 cells before cesium chloride
(CsCl) purification, as previously described.10,11,29,43 Viruses
were then quantified by measuring particle counts and tissue
culture inhibitory dose 50% (TCID50) assays. In all infection
experiments, multiplicity of infection (MOI) was defined as pla-
que-forming units (pfu)/cell. Cells were infected for 48 h prior
to co-culture with NK cells for a further 24 h. MOIs were selected
based upon dose response curves with the chosen cell lines as
determined by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide) assays post-infection (Figures S10 and S11),
as previously described.10
Infectability of NK Cells
NK-92, PBMCs, cells from ascites, purified pNKs, and OC lines
(including TOV21G) were incubated with Ad CMV GFP (MOI
10), dl922-947 (MOI 10), and NG-107 (MOI 100) for 48 h
before flow cytometric and immunofluorescence assessment ofMolecuinfectability. Because there is not a GFP-en-
coding derivative of dl922-947, adenovirus
protein expression was assessed by immuno-
fluorescence using an anti-adenovirus primary
antibody (Ab36851; 1 in 100; Abcam, UK).
Cells were counterstained with DAPI. Imaris
software (Version 9.3.1; Bitplaine, Switzerland)
was used to identify immunofluorescent cells.
Briefly, individual cells were identified by
DAPI (40,6-diamidino-2-phenylindole) staining
and counted. For each experiment, the fluo-
rescence intensity (GFP or Alexa Fluor 594)
of mock-infected pNK cells was used to define
the minimum fluorescence intensity of positive
(i.e., infected) cells. The same algorithm was
then applied to all images in the same exper-iment and positive/infected cells were identified and counted. To
allow direct comparisons between groups and replicates, we
calculated percentages of positive/infected cells.
Evaluation of CD107a, CD69, and NK Receptors
For co-culture experiments, TOV21G and OVCAR4, with or without
dl922-947 (MOI 10, 48 h) and enadenotucirev (MOI 100, 48 h) infec-
tion, were incubated with 5  105 PBMCs from healthy donors in
96-well plates at 1:1 ratio in a total volume of 100 mL. Similarly, for
the conditioned medium experiments, cell-free conditioned medium
from dl922-947 (MOI 10, 48 h) and enadenotucirev (MOI 100, 48 h)
infected TOV21G and OVCAR4 was incubated with 5  105 PBMCs
from healthy donors in 96-well plates in a total volume of 100 mL.
To collect cell-free conditioned medium, we plated 106 OC cells
(OVCAR4, TOV21G) on 6 cm plates before infection with dl922-
947 (MOI 10) or enadenotucirev (MOI 100) in a total volume of
1.5 mL. Cell-free medium was collected 48 h after infection. For
CD107a and CD69, the mixtures were incubated for 5 h at 37C in
the presence of monensin (GolgiStop, 1:1,000, cat number: 554724,lar Therapy: Oncolytics Vol. 16 March 2020 297
(legend on next page)
Molecular Therapy: Oncolytics
298 Molecular Therapy: Oncolytics Vol. 16 March 2020
www.moleculartherapy.orgBD Biosciences, Berkshire, UK) and conjugated antibodies for CD3,
CD56, and degranulation marker CD107a or activation marker
CD69 in a total volume of 150 mL. Cells were washed and stained
by fixable viability dye before fixation and flow cytometric evaluation.
For cell surface NK receptors NKp46 (clone 9E2), CD96 (clone
NK92.39), DNAM-1 (clone 11A8), and TIGIT (clone A15153G),
the mixtures were incubated for 18 h at 37C before flow cytometric
evaluation.
IFN-g Detection by ELISA
In co-culture experiments (CC), 104 target cells (TOV21G and OV-
CAR4 infected with dl922-947 [MOI 10] or enadenotucirev [MOI
100] for 48 h) were incubated with 105 pNK cells or no-NK culture
medium (RPMI with 10% FBS) for 24 h in a 96-well plate at a total
volume of 200 mL (E:T ratio 10:1). In the conditioned medium exper-
iments (CM), cell-free conditioned medium from mock-infected or
virus-infected cells was added to 105 pNK or no-NK culture medium
(RPMI with 10% FBS) for 24 h in a 96-well plate at a total volume of
200 mL. At the end of the incubation period (24 h) for both groups
(CC and CM), the plate was centrifuged (430 g, 5 min), and the super-
natant collected for IFN-g assessments by ELISA (Human IFN-g
ELISA MAX Deluxe kit, cat number 430104; Biolegend, San Diego,
CA), according to the manufacturer’s instructions.
Assessment of NK Cytotoxicity by Live Cell Analysis System
NK-92, pNK, or ascites NK cells were co-cultured with dl922-947-in-
fected (MOI 10, 48 h post-infection), enadenotucirev-infected (MOI
100, 48 h post-infection), mock-infected TOV21G and OVCAR4 or
conditioned medium from each group at an effector-to-target (ET)
ratio of 10:1 in flat-bottom 96-well plates in triplicate at 3,000 cells
per well. Fluorescent Cytotox nucleic acid dye was used for identifica-
tion of dead cells. Images were assessed using an IncuCyte Live Cell
Analysis System (Essen Biosciences, Ann Arbor, MI) to identify the
dead cells (as fluorescent objects) in each image (two 10magnifica-
tion images from different areas per well were captured every hour).
Dead NK cells were excluded from analyses based on size (the mini-
mal surface area for a fluorescent object to be included was 125 mm2).
The TAUC of fluorescent object counts over time was used to quan-
tify overall NK killing. Target-only and NK-only controls were
routinely used for these experiments.
Assessing NK Cytotoxicity by Flow Cytometry
TOV21Gwere plated in 24-well plates at 104 cells per well. After over-
night incubation, cells were either mock-infected or infected with
dl922-947 (MOI 10). 48 h post-infection, NK-92 or human pNK
were added (ET ratio of 10:1). Cells were harvested after 18-h co-cul-Figure 6. DNAM-1 Blockade Attenuates and TIGIT Blockade Augments NK-Me
The changes of NK receptors on pNK after exposure to adenovirus-infected TOV21G or
independent experiments (n = 5) for DNAM-1 (left) and TIGIT (right) expression. (B) Rep
tests; CC, co-culture; CM, conditioned-medium). pNK were co-cultured with dl922-94
assessed by time-lapse microscopy. (C) Representative data of fluorescent object coun
and (D) OVCAR4 (n = 3) are shown (one-way ANOVAwithmultiple comparisons test). (E)
TIGIT antibody (20 mg/mL) and assessed by time-lapse microscopy (n = 5, each line reture, washed once and stained with surface marker CD45 for NK cells
(Clone 2D1, Biolegend, San Diego, CA) and fixable viability dye (cat
number 423113, Biolegend, San Diego, CA). Cell death in CD45-
negative target TOV21G cells was determined by flow cytometry.
Target-only and NK-only controls were also used in these
experiments.
NK-Mediated Killing of Uninfected Tumor Cells
Target TOV21G and OVCAR4 cells (2 104/well) were plated on 12-
well plates. After mock, dl922-947 (MOI 10, 48 h) or enadenotucirev
(MOI 100, 48 h) infection, pNK (ET ratio 5:1) or no-NK culture me-
dium (negative control) was added to each well. Uninfected cells
(TOV21G and OVCAR4, 2  104/well) were marked by CellTracker
Green CMFDA Dye (2 mM, C7025, Thermo Fisher Scientific, USA)
and added to target cells 4 h after initiation of NK/infected target
cell co-culture. After a further 18-h incubation, supernatants and cells
were collected and centrifuged (430 g for 5 min). Viability of unin-
fected CellTracker green cells was determined by flow cytometry.
Additional NK-mediated killing was calculated by subtracting the
percentage of cell death in the no-NK controls from that in the
pNK groups.
Transwell Assays to Assess NK Bystander Killing
Contact-dependence of pNK cytotoxicity against dl922-947-infected
TOV21G was evaluated by assessing cell death of dl922-947-infected
TOV21G in 0.4 mm transwells. TOV21G (104/well) were plated on the
bottom of a 12-well plate and on the 0.4-mm-pore polycarbonate 12-
well transwell inserts (12 mmmembrane diameter; cat number: 3401,
Corning, USA). After mock or dl922-947 infection (MOI 10, 48 h),
pNK (105; ET 10:1), or no-NK culture medium (negative control)
was added to the bottom of the well. After an 18-h incubation, the in-
serts were carefully removed without spillage into a separate 12-well
plate. The supernatants and trypsinized TOV21G of each group were
combined and centrifuged (430 g for 5 min) before staining with
viability dye and CD45 antibody (Clone HI30; Biolegend, San Diego,
CA). Cell death in CD45-negative target TOV21G cells was deter-
mined by flow cytometry.
Recombinant Human Fc Chimera Protein and Flow Cytometry
for Detection of NK Ligands
As multiple NK ligands can bind to a single NK receptor, NK ligand
expression on infected OC cells was evaluated using recombinant hu-
man Fc chimera proteins. Recombinant human Fc chimera proteins
consist of human immunoglobulin G1 (IgG1) and the relevant bind-
ing portion of the proteins of interest. These binding portions can
bind with multiple relevant NK ligands of the corresponding NKdiated Cytotoxicity against Adenovirus-Infected Cells
their conditioned media were evaluated by flow cytometry. (A) Summary analyses of
resentative images of DNAM-1 (left) and TIGIT (right) expression (Mann-Whitney U
7-infected cells with or without a blocking anti-DNAM-1 antibody (10 mg/mL) and
ts over time for TOV21G (left) and summary data (n = 5) of TAUC for TOV21G (right)
pNKwere co-culturedwith OV-infected TOV21G cells with or without a blocking anti-
presents a unique donor; also see Figure S8).
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and target ligands could be influenced by treatment conditions,44,45
the fold change in MFI between relevant Fc chimera and control Fc
protein was used to compare differences between groups.
Cells were stainedwith recombinant human Fc chimera proteins (R&D
Systems, Minneapolis) or conjugated antibodies (all from Biolegend,
San Diego, CA) against MHC class I proteins (clone W6/32), CD112
(clone TX31), and CD155 (clone SKII.4). As the antibody against hu-
man Fc-protein was conjugated with biotin, tertiary antibody staining
was assessed with Streptavidin-PE in 50 mL at 1:1,000 for 30 min at
4C–8C in the dark (Figure 5B, cat number 405203, Biolegend, San
Diego, CA). Cells were washed twice with 150 mL of FACS buffer,
centrifuged (430 g, 5 min, 4C) and supernatant discarded.
DNAM-1 and TIGIT Blockade
Human NK cells were rested in culture medium for 1 h, with or
without anti-DNAM-1 (MAB666, R&D Systems, Minneapolis, MN;
final concentration 10 mg/mL)17 or anti-TIGIT (MAB78981, R&D
Systems, Minneapolis, MN; final concentration 20 mg/mL) antibody,
before co-culture with target cells (with or without OV infections).
Cell-free mediumwith appropriate antagonists and no target cell con-
trols was routinely used as control.
Statistical Analyses
All statistical analyses were performed using Prism (v8.0, GraphPad,
La Jolla, CA). Data are presented as mean ± SEM unless otherwise
stated. Paired analyses (one-way ANOVA with multiple comparison
tests, t tests, or their non-parametric equivalent) were used for anal-
ysis of repeated experiments, and p < 0.05 was considered significant
throughout. Unless otherwise stated, each symbol/point represents
the average value of an independent experiment. In all figures, ns =
not significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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